Sorrento Therapeutics, an antibody-centric, clinical-stage biopharmaceutical company, and Yuhan Corporation, one of the largest pharmaceutical companies in South Korea, entered into an agreement to form a joint venture company—ImmuneOncia Therapeutics—to develop and commercialize a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors. The creation of ImmuneOncia strengthens the presence of both companies in the field of immuno-on...